Search for fat-soluble ligand of nuclear orphan receptor.
Search for fat-soluble ligand of nuclear orphan receptor.
批准号:
05660106
负责人:
KATO Shigeaki
金额:
$1.34万
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1993
资助国家:
日本
项目状态:
已结题
起止时间:
1993 至 1994
中文摘要
类固醇/甲状腺/维生素A,D核受体形成一个基因超家族,它们在结构和功能方面彼此相似。除了已发现配体的核受体外,还存在配体未知的孤儿受体。当孤儿受体的配体被鉴定出来时,一条新的信号通路就变得清晰起来。在本研究中,维生素A受体(RAR,RXR)和维生素D受体(VDR)以及孤儿受体的亚型和同种型已被搜索的cDNA编码RAR,RXR和VDR从各种哺乳动物组织的cDNA文库。因此,我们发现了VDR亚型(VDR 1)作为一个显性负性受体对野生型VDR(VDR 0)。考虑到维生素D的多种活性形式对生物学作用的存在,这些化合物之一可以作为VDR 1的配体。此外,已鉴定孤儿受体的功能分析正在研究中。
英文摘要
Steroid/thyroid/vitamin A,D nuclear receptors form a gene superfamily, and they resemble each other in terms of structure and function. Besides of the nuclear receptors, whose ligands have been found, receptors with unknown ligands exist as "orphan receptor" . When the ligand for orphan receptor will be identified, a new signaling pathway becomes clear. Moreover, a cross-talk with the signaling pathways for fat-soluble ligands will be clarified.In the present study, the subtypes and isoforms for vitamin A receptors (RARs, RXRs) and vitamin D receptors (VDR) as well as orphan receptors have been searched with cDNAs encoding RAR,RXR and VDR from the cDNA libraries of various mammalian tissues. Consequently, we found a VDR isoform (VDR1) acting as a dominant negative receptor against the wild type of VDR (VDR0). Considering the presence of multiple active forms of vitamin D on biological actions, one of these compounds may act as a ligand for VDR1. In addition, the functional analysis of identified orphan receptors is under investigation.
期刊论文(44)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
R.Kojima, et al.: "In vivo isomerization of retinoic acid : rapid isomer exchange and gene expression." J.Biol.Chem.269. 32700-32707 (1994)
R.Kojima 等人:“视黄酸的体内异构化:快速异构体交换和基因表达。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Y.Kamei: "Vitamin D receptor gene expression is up‐regulated by 1,25‐dihydroxyvitamin D3 in 3T3‐L1 preadipocytes" Biochem.Biophys,Res.Commun.193. 948-955 (1993)
Y.Kamei:“3T3-L1 前脂肪细胞中维生素 D 受体基因表达被 1,25-二羟基维生素 D3 上调”Biochem.Biophys,Res.Commun.193 (1993)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
R.Kojima,et al.: "In vivo isomerization of retinoic acid:rapid isomer exchange and gene expression." J.Biol.Chem.269. 32700-32707 (1994)
R.Kojima 等人:“视黄酸的体内异构化:快速异构体交换和基因表达”。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
加藤茂明: "受容体の分子生物学" 日本臨床 日本臨床社, 17-23(7) (1994)
加藤茂明:“受体的分子生物学” Nippon Clinic Nippon Clinic,17-23(7) (1994)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
H.Sasaki,et al.: "Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR mediated gene expression." Biochemistry. 34. 370-377 (1995)
H.Sasaki 等人:“氟化维生素 D 类似物对 VDR-RXR 介导的基因表达的转录活性。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 22 条
The role of the nuclear receptors in cancer development
-
批准号:17013023
-
项目类别:Grant-in-Aid for Scientific Research on Priority Areas
-
资助金额:$30.46万
-
财政年份:2005
-
负责人:KATO Shigeaki
-
依托单位:
Identification and characterization of novel complexes controling chromatin structure
-
批准号:16207009
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$28.79万
-
财政年份:2004
-
负责人:KATO Shigeaki
-
依托单位:
Mechanism of transcriptional regulation by nuclear receptors
-
批准号:12219206
-
项目类别:Grant-in-Aid for Scientific Research on Priority Areas
-
资助金额:$80.06万
-
财政年份:2000
-
负责人:KATO Shigeaki
-
依托单位:
Search of novel nuclear orphan receptors for fat-soluble ligands
-
批准号:11460035
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$9.6万
-
财政年份:1999
-
负责人:KATO Shigeaki
-
依托单位:
Establishment of nuclear receptor-mediated assay for sex-steroid like compounds
-
批准号:11556065
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$8.32万
-
财政年份:1999
-
负责人:KATO Shigeaki
-
依托单位:
Molecular mechanism of vitamin A and vitamin D actions
-
批准号:09556073
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.9万
-
财政年份:1997
-
负责人:KATO Shigeaki
-
依托单位:
Development of novel assay system based on nuclear receptor function
-
批准号:09460044
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.32万
-
财政年份:1997
-
负责人:KATO Shigeaki
-
依托单位: